{
    "nct_id": "NCT00622713",
    "title": "A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)",
    "status": "COMPLETED",
    "last_update_time": "2011-06-27",
    "description_brief": "This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm\\^2 in patients with probable Alzheimer's Disease (Mini-Mental State Examination 10-26) in the community setting",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Rivastigmine Transdermal Patch",
                    "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "228"
                                }
                            ]
                        },
                        {
                            "type": "Exposed to Study Drug",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "226"
                                }
                            ]
                        },
                        {
                            "type": "Intent to Treat (ITT) Population",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "218"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "169"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "59"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "35"
                                }
                            ]
                        },
                        {
                            "type": "Administrative problems",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "11"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Death",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Subject no longer required study drug",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Did not meet eligibility criteria",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Rivastigmine Transdermal Patch",
                    "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "218"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age Continuous",
                    "description": "Baseline Measures are provided for the ITT population.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "78.7",
                                            "spread": "6.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "131"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "87"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "France",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "218"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study",
                    "description": "The primary endpoint was the percentage of patients who were able to tolerate (and stay on for at least 8 weeks) rivastigmine target patch size 10 cm\\^2.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Transdermal Patch",
                            "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "218"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "70.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Clinical Global Impression of Change (CGI-C) by Physician",
                    "description": "The CGIC is an assessment tool used by a clinician to make a judgment of the severity or a change of a patient's condition. The clinician relies solely on information obtained from the patient at the Baseline visit as well as clinical information obtained throughout the study period. The CGIC is rated on the following seven-point scale:\"very much improved\", \"much improved\", \"slightly improved\", \"unchanged\", \"slightly worsened\", \"much worsened\" and \"very much worsened\".",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time. Last observation carried forward (LOCF) was used for missing values.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "Baseline and week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Transdermal Patch",
                            "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "208"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Very much improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.3",
                                            "spread": "5.2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Much improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "13.0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Slightly improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23.1"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Unchanged",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "32.2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Slightly worsened",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Much worsened",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5.8"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Very much worsened",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline to Week 24 in the 4-item Instrumental Activities of Daily Living (4-IADL) Score",
                    "description": "The 4-IADL assesses the ability of a patient to autonomously perform 4 activities of daily living: Use the telephone, take medications, use public transport, and manage their own budget. Each activity is assessed by a series of questions and rated on a scale of 1 to 4. Scores on the 4 activities are combined for a total score ranging from 1 to 16. A lower score indicates a more self-sufficient individual. A positive change from baseline score indicates worsening.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "Baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Transdermal Patch",
                            "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "218"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline (n= 198)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.2",
                                            "spread": "1.18"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 24 (n= 181)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.2",
                                            "spread": "1.16"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Change from Baseline to week 24 (n= 172)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.1",
                                            "spread": "0.74"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline to Week 24 in the Mini-Mental State Examination (MMSE) Score",
                    "description": "The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score from 0 to 30, with higher scores indicating better function. A positive change score indicates improvement from baseline.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "Baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Transdermal Patch",
                            "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "218"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline (n = 216)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.2",
                                            "spread": "4.11"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 24 (n = 203)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.2",
                                            "spread": "5.19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Change from baseline to week 24 (n = 203)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.0",
                                            "spread": "3.18"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline to Week 24 in the Mini-Zarit Inventory Score",
                    "description": "The Mini-Zarit Inventory assesses the burden of a caregiver in caring for a patient. The inventory is composed of 5 questions which are rated according to the following answers: 0 = never, \u00bd = sometimes, 1 = often. The ratings on the 5 questions are added together resulting in a total score of 0 to 7 with a higher score indicating greater caregiver burden.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Transdermal Patch",
                            "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "218"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline (n= 211)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.8",
                                            "spread": "1.76"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 24 (n= 199)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.9",
                                            "spread": "1.85"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Change from baseline to week 24 (n= 197)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.1",
                                            "spread": "1.35"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "description": "Safety population.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Rivastigmine Transdermal Patch",
                    "description": "During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\\^2.",
                    "seriousNumAffected": 21,
                    "seriousNumAtRisk": 218,
                    "otherNumAffected": 13,
                    "otherNumAtRisk": 218
                }
            ],
            "seriousEvents": [
                {
                    "term": "LYMPHADENOPATHY",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "ACUTE CORONARY SYNDROME",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "BRADYCARDIA",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "CARDIAC ARREST",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "NAUSEA",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "SIGMOIDITIS",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "VOMITING",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "MALAISE",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "OEDEMA PERIPHERAL",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "CHOLECYSTITIS",
                    "organSystem": "Hepatobiliary disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "CHOLELITHIASIS",
                    "organSystem": "Hepatobiliary disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "HEPATOMEGALY",
                    "organSystem": "Hepatobiliary disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "HYPERSENSITIVITY",
                    "organSystem": "Immune system disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "BRONCHITIS",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "LUNG INFECTION",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "VIRAL INFECTION",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "FALL",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "FEMORAL NECK FRACTURE",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "FOREARM FRACTURE",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "WRIST FRACTURE",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "BIOPSY PROSTATE",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "DIABETES MELLITUS",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "MUSCULOSKELETAL CHEST PAIN",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "METASTATIC NEOPLASM",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "PROSTATIC ADENOMA",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "SQUAMOUS CELL CARCINOMA",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "AUTONOMIC NERVOUS SYSTEM IMBALANCE",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "DYSSTASIA",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "EPILEPSY",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "APATHY",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "DYSPNOEA EXERTIONAL",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "PULMONARY EMBOLISM",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "DERMATITIS ALLERGIC",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "PRURITUS",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "RASH",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "SOCIAL STAY HOSPITALISATION",
                    "organSystem": "Social circumstances",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "HIP ARTHROPLASTY",
                    "organSystem": "Surgical and medical procedures",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                },
                {
                    "term": "MALIGNANT TUMOUR EXCISION",
                    "organSystem": "Surgical and medical procedures",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 218
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "ERYTHEMA",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 218
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."
            },
            "pointOfContact": {
                "title": "Study Director",
                "organization": "Novartis Pharmaceuticals",
                "phone": "862-778-8300"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "rivastigmine patch (10 cm^2; Exelon patch, transdermal rivastigmine)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is a rivastigmine transdermal patch (10 cm^2). Rivastigmine is a cholinesterase inhibitor that increases synaptic acetylcholine by inhibiting acetylcholinesterase and butyrylcholinesterase; its clinical effect is symptomatic\u2014improving cognition and function in Alzheimer\u2019s disease\u2014rather than established disease modification. \ue200cite\ue202turn0search7\ue202turn0search0\ue201",
        "Act: Key extracted details from the trial description \u2014 24-week, multicenter, open evaluation of the once-daily 10 cm^2 rivastigmine patch in patients with probable Alzheimer\u2019s disease (MMSE 10\u201326). The 10 cm^2 patch corresponds to approximately 9.5 mg/24 h in clinical studies of the Exelon (rivastigmine) patch formulation. This is a symptomatic treatment intended to improve cognition/tolerability/compliance, matching the cognitive enhancer category. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Reflect: Classification check \u2014 per mechanism (cholinesterase inhibition) and intended clinical effect (cognitive/functional improvement, caregiver convenience), the trial fits the 'cognitive enhancer' category. It is not a biologic (monoclonal antibody or vaccine) nor a small-molecule disease-modifying agent aimed at amyloid/tau pathology; rivastigmine is a small-molecule symptomatic cholinesterase inhibitor. The trial is an open effectiveness/tolerability study, not a diagnostic study, so 'N/A' does not apply. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Web search results (key sources used): 1) PubMed trial comparing rivastigmine patch sizes and reporting 10 cm^2 = 9.5 mg/24 h and efficacy/tolerability data (IDEAL study). \ue200cite\ue202turn0search1\ue201 2) Reviews and drug monographs describing rivastigmine mechanism (AChE and BuChE inhibition) and available patch doses (4.6, 9.5, 13.3 mg/24 h). \ue200cite\ue202turn0search7\ue202turn0search5\ue201 3) Clinical reviews and OPTIMA/other patch studies showing cognitive/functional benefit and dosing data for 10 cm^2 and higher patches. \ue200cite\ue202turn0search6\ue202turn0search8\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests a rivastigmine transdermal patch, a cholinesterase inhibitor that increases synaptic acetylcholine (by inhibiting acetylcholinesterase and butyrylcholinesterase) and is used as a symptomatic cognitive enhancer in Alzheimer\u2019s disease. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 rivastigmine (Exelon) patch, 10 cm^2 corresponds to ~9.5 mg/24 h and is administered once daily as a symptomatic cognitive enhancer to improve cognition/function in AD rather than to modify amyloid/tau pathology. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search3\ue201",
        "Reflect: Mapping to CADRO \u2014 this intervention modulates the cholinergic neurotransmitter system (increasing acetylcholine levels) rather than targeting amyloid, tau, inflammation, or proteostasis. The most specific CADRO match is D) Neurotransmitter Receptors (neurotransmitter-system modulation / symptomatic cognitive enhancement). The classification is not R) Multi-target (single primary mechanism) nor T) Other (therapeutic, not diagnostic). \ue200cite\ue202turn0search7\ue201",
        "Web search results used: 1) StatPearls summary of rivastigmine mechanism and patch strengths (AChE and BuChE inhibition; patch 4.6/9.5/13.3 mg/24h). \ue200cite\ue202turn0search0\ue201 2) PubMed (Brain Research) article showing rivastigmine inhibits AChE and BuChE in plaques/tangles. \ue200cite\ue202turn0search1\ue201 3) Exelon (SmPC / medicines.org.uk) dosing and 9.5 mg/24h (10 cm^2) details. \ue200cite\ue202turn0search2\ue201 4) FDA/DailyMed Exelon patch prescribing information (dosing/titration and indications). \ue200cite\ue202turn0search3\ue201 5) Novartis product information/press describing clinical use as symptomatic cognitive treatment and safety considerations. \ue200cite\ue202turn0search5\ue201"
    ]
}